- FDA accepted BLA and granted Priority Review for ifezuntirgene inilparvovec in Huntington's disease.
- PDUFA target action date set for May 1, 2027.
- Alignment reached on confirmatory study design with U.S. patient screening initiating by end of 2026.
?? Positive AI Sentiment (+7.5 / 10)
Observed market reaction after signal
Peak +8.22%